Sanofi (NASDAQ:SNY)

Strategy Session February 9th, 2017

View Entire Video (25:51)
Strategy Session
February 15th, 2017
   00:21
Strategy Session
February 9th, 2017
   00:11
Strategy Session
February 8th, 2017
   00:38
Bands Volume 200 SMA 50 SMA 20 SMA Videos Alerts Articles Events
SNY Weekly Chart

Old Forum Content for SNY

Make a Forum Post
Become a member to view recent forum posts. Already a member? Sign in here.
Loading...
  • woodman: $NKTR - still holding this. It's been quite a move since $SNY's competing drug had bad data. But things could change quickly if the fickle biotech gods decide it's time. But until then, lots of biotechs are doing well.
  • woodman: $NKTR could run today due to bad data on $SNY's competing drug. Or, in ordinary biotech fashion, it could pop early then give it back. One never knows.
  • MongosPawn: @woodman $MREO $SNY $INBX Just seeing this post now. Thanks again for all the great info. I did add some last week. Am now at about 35% of a typical stock full position, but for my bio-techs I'm at about 70% of a full bio position. FWIW.
  • woodman: @sierramp $MREO $SNY $INBX - I can't emphasize enough that biotech investing is brutal. too often indiscriminately cruel, and can make anyone look like a fool in the snap of a finger, so it's important to invest at your comfort level should things go south.
  • woodman: $MREO @sierramp @MongosPawn @Onthemark et al. - this $2.2 billion deal for $SNY to buy $INBX's AATD drug candidate bodes well for $MREO. See https://inhibrx.investorroom.com/2024-01-23-Inhibrx-Announces-Sale-of-INBRX-101-to-Sanofi-for-an-aggregate-value-of-up-to-2-2B MREO's drug candidate for AATD lung disease (Alvelestat) has two Phase 2 trials completed with over 160 patients recruited and has a validated path forward to Phase 3 with potential partnering on the horizon (also being tested for Bronchitis Obliterans Syndrome) is further along than $INBX's just-purchased drug (in Phase 1 single arm trial with 31 patients enrolled and a confused path forward). MREO also has a Phase 3 study of setrusumab (data due end of 1Q) for treatment of Osteogenesis Imperfecta (OI - bone deformities and weak bones) These drugs are multi-billion dollar opportunities, especially AATD-LD. At $471 mil market cap, MREO looks cheap.
  • woodman: $MREO $SNY $INBX - I'm kicking myself for failing to add to $MREO this morning. I had it teed up for an add around $3.00, but didn't do it.
  • sierramp: @woodman $MREO $SNY $INBX That's what caused the beautiful move in $MREO today, nice! Thank you. I was looking for news on $MREO but didn't look for collateral stock news. You have a very good nose for these stocks. Too bad you missed your buy point but I suspect you have a good position. I've only got about a quarter of a full position but because of the volatility of biotech, that is my comfort level. Thank you for letting us know what is happening. Hopefully we'll see more of this action.
  • mharps: $SNY added a little
  • JosephM: $SNY/$WELL..don't know the name but looks like a reversal day with volume.
  • kycol: #Covid_Bio Here is my Covid_Bio watchlist: $AZN $BNTX $GSK $JNJ $MRNA $NVAX $PFE $SNY Currently long $JNJ & $PFE. I may take a starter position in $SNY today. News is that the Admin is looking for Covid booster shots for all starting in Sept.
  • kycol: @bRobert $nvax On my Menervini Scan, 28stocks are green; $NVAX is Nr 2 & $SNY Nr 20; long both
  • bRobert: @kycol $nvax $NVAX $SNY Nvax potential is huge with very manageable risk Again a weekly breakout has $500+ potential. Lower float in nvax compared to MRNA and bntx will magnify move with a huge earnings revenue uptick
  • DAN: @kycol $AZN $BNTX $GSK $JNJ $MRNA $NVAX $PFE $SNY #Covid_Bio Great list, kycol.
  • wijimmy: $REGN .... Regeneron's Libtayo Wins FDA Approval For A Type Of Skin Cancer.. $REGN and Sanofi SA $SNY immunotherapy Libtayo (cemiplimab-rwlc) has scored approval from the FDA for the treatment of advanced basal cell carcinoma (BCC), the most common type of skin cancer in the U.S... Was excepting more today with this FDA approval... L/T hold $JPM Valuation Our {$JPM} Dec 2021 price target of $540 is based on a DCF analysis of the company, assuming a 7.5% discount rate and a 1.0% terminal growth rate. Risks to Rating and Price Target Downside risks include (1) a meaningful slowdown of Eylea/Dupixent growth, (2) additional competition for commercial products, and (3) negative headlines from the pipeline. Upside risks include (1) continued strong adoption of Eylea/Dupixent and stronger-than-expected uptake in recently approved indications, (2) competition being less relevant than expected, and (3) better- than-expected uptake for other recently commercialized products (for ex Praluent, Kevzara, and Libtayo).
  • Ajax4Hire: Bio-Technology; Bio=Life; Techno=art/craft/skill; logy=study of BioTechnoLogy=Life-Craft-Study, aren't we all bio-technologist. Hold% $IBB iShares Nasdaq Biotechnology ETF - Top 15 holdings 7.93% $AMGN Amgen Inc 7.87% $VRTX Vertex Pharmaceuticals Inc 7.45% $GILD Gilead Sciences Inc 6.51% $REGN Regeneron Pharmaceuticals Inc 5.54% $ILMN Illumina Inc 3.37% $BIIB Biogen Inc 3.11% $SGEN Seattle Genetics Inc 2.68% $ALXN Alexion Pharmaceuticals Inc 2.57% $MRNA Moderna Inc 2.43% $INCY Incyte Corp 2.31% $BMRN Biomarin Pharmaceutical Inc 1.83% $ALNY Alnylam Pharmaceuticals Inc 1.38% $SRPT Sarepta Therapeutics Inc 1.24% $NBIX Neurocrine Biosciences Inc 1.21% $SNY Sanofi SA Data from: https://ETFdB.com/etf/IBB/#holdings
  • Sher: ...
    Conspicuous by their absence are GlaxoSmithKline ($GSK 0.4%) and Sanofi ($SNY -0.5%).

  • Sparrows: $REGN blasted up $15 in the last 10 mins of trading, and 100k shares changed hands in the last min. Will be interesting to see where this stock goes on Monday. Very high volumes in the last 4 days since the $SNY announcement.
  • Sparrows: @bRobert Do you have a view on $REGN for the long run, few weeks or longer? Yesterday heavy selling along with rest of biotech, but also b/c $SNY is getting out of it's ownership. volume is pretty big today, up by 1.3%, $30 from LOD.
  • bRobert: @Sparrows $REGN $SNY There was selling in biotech. $REGN trading bounce off the 50d. Stop just below I t will follow the general biotech market.
  • Sparrows: @bRobert $REGN $SNY Thanks!
  • joelsg1: $BMRN Breaks through resistance with volume on $SNY takeover rumor but heading there regardless
  • Sher: Been taking profits on several front month call positions (day/swing trades): Friday: $INO, $SNY Monday: $CRWD, $DBX, $FCEL, $GNMK, $INO (3rd in/out trade) Today: $SDC (out of all positions on huge AM pop) New positions, today (prospective earnings runs): $AG (thanks Scott) – May $8.00 calls – ER on the 14th $CIEN – May $40 calls – ER not until June – Lousy entries (caught in phase 2 PB) $EWZ – May $22 calls - MAs seriously reversed, but back above the 8, 20 and VW averages - Temp. bottom in on Friday - Nice pickup in money flow and momentum, this week - Up 6.5%, today. $INSG – Added to May $15 calls put on, yesterday, after taking nice gains on May $12 calls, prior – Due to report on the 6th. $NIO – May 29th (weekly) $3.00 calls – ER May 25th. $SPR – May $20 – ER May 6th. - In at $1.65/share.
  • jbuc5222: $SNY. breaking out of a 5 min squeeze... reported earnings this morning
  • mgoodw: @Sher $SNY $INO Adding to your $SNY position today?
  • Sher: New positions (earnings runs, hopefully): $INSG (May $12.50 calls) – Probably not the best entry on this one... ER May 6th, A/C - Guided Q1 revenue above consensus on the 8th – Sees Q2 revenue in the range $75M-$85M (current consensus, $52M). $OPK (May $2.00 calls) – ER May 5th, A/C - The company's Bioreference Lab unit provides COVID-19 testing services – Currently trading @ $2.09. Taking profits, for now, on $JNUG (calls), $SNY (calls)… not acting well, today (ER on the 24th) and $VXRT (stock). $SBSW – Added to May $7.50 calls - Anticipating phase 3 reversal as gold advances. $CDE - More of a spec trade, at this point, since it hasn't performed worth a “twit” - However, money flow has been picking up the past 3-4 days, so looking for this to catch the gold bug – Have been adding to underwater May call position (not recommended).
  • issues: @Sher $INSG $OPK $JNUG $SNY $VXRT $SBSW $CDE We bought $INSG. Cramer had the CEO on last night. Impressive. Would add on a BO!
  • Sher: $SNY - Watch this one to join the "vaxer" fray - Momentum and money flow picking up - Like the chart - Long and adding to May $48 calls, which are up 103%, to date.
  • Bsielingtx: @Sher $SNY like a rocket, I am long the same calls!
  • AndStars: @Sher $SNY May $48 calls. Following. In on the dip at $1.94. Thanks Sher!
  • Sher: $SNY - Options quotes are pretty schizophrenic - Have added twice, today, doubling original position (May $48 calls) @ $1.75/share - Bid/ask, at the time, was $1.65 - $2.55 - It's a bit like throwing darts at a moving board! Also adding to $INO on PBs...
  • wijimmy: @Sher $SNY $INO ..Why not just take some $SNY stock at $48 rhrn ?? earnings 4/24.. NP
  • Sher: @wijimmy $SNY $INO - I'll be out of my call position prior to earnings...
  • Laws13: @Sher $SNY $INO Sher, when do you show earnings for INO?
  • AndStars: @Sher $SNY Out for a slight loss. Don't want to hold this overnight.
  • debeers: $CI and $BX-sent to their room and can come back and play with the ohers when it behaves. $LABU from the open $AXSM, $EBAY, $INMD, $SNY, $TDOC, $WMT (which i still think will buy my $EBAY.
  • Sher: ...
    $SNY – Just added this to the above coronavirus plays - MAs are reversed from prior PB, but today's gains have put the stock back above both the 50-day and VW averages – Went long with May $48 calls @ $1.10/share.

    Prior product posts:
    ...
  • jr3345: @Sher $BCRX $CANF $INO $VXRT $SNY thanks, very informative
  • Sher: @jr3345 $BCRX $CANF $INO $VXRT $SNY - You're welcome...
  • captron: @Sher $BCRX $CANF $INO $VXRT $SNY Thank you Sher. Your research has always been useful and rewarding. Have a great weekend.
  • Sher: @captron $BCRX $CANF $INO $VXRT $SNY - You, as well... and thank you for your post.
  • Kid2old: @Sher $BCRX $CANF $INO $VXRT $SNY Thank you for the recap. I will consider these companies after this weekend’s research. By the way I follow some of your post, but I do not do options, I just buy the shares. I have done a few covered calls in the past, as suggested in the forum by members. I am looking at the “sell the put at the price you want to buy at”.
  • jonwest88: @debeers $SNY $AXSM $INMD $CI $EBAY $LRCX $SFT $TSM $WMT $BA Looked to add more $INMD yesterday but re added some to my $MA shares that were sold in 2019 at higher prices. $MA is up 5.5 % from yesterday's add, and $INMD add would have been up about 6.5%. I am still looking to add to $INMD. Plenty of time, and I did take a shot and add more @17.5. I will look at Dan's sell the put option strategy to add, as long as the bid ask spread is not insanely ridiculous.
  • debeers: Report Card for today with 40 mins to go-delete SFT meant $SNY
    $AXSM+5.33%
    $INMD 8.81%
    $CI- -1.64%
    $EBAY- down .32% )Oh the horrors!)
    $LRCX- 2.49% reporting next week and they make the wafers for the Taiwan semi chips---yes ALL the wafers

    $SNY- 1. ...
  • Herb: ...
    Sanofi $SNY is a large-cap pharmaceutical company. It has now collaborated with the US Biomedical Advanced Research and Development Authority (BARDA) to develop vaccine candidates against COVID-19. This Zacks Rank #3 company’s expected earning ...
  • Bridget: @Herb $REGN $MRNA $INO $NVAX $SNY #1 #1 #2 #3 #3 #3 Thanks for this information, very helpful.
  • Herb: @Bridget $REGN $MRNA $INO $NVAX $SNY #1 #1 #2 #3 #3 #3 It kind of explains why $REGN seems to be trading in a different universe.
  • Sher: @Herb $REGN $MRNA $INO $NVAX $SNY - Thanks Herb... Great post!
  • Auto: @Herb $REGN $MRNA $INO $NVAX $SNY #1 #1 #2 #3 #3 #3 Thumbs up! Thanks
  • mariemicheles: @Herb $REGN $MRNA $INO $NVAX $SNY #1 #1 #2 #3 #3 #3 Thanks for the post Herb.
  • issues: Buffett's Berkshire Hathaway's $BRKB latest 13-F filing, showed a bigger stake in Apple $AAPL and purchased the following: $BAC $GS $DAL $TRV $JPM $STNE $GM (really Warren?? GM?) $USB ORCL. He sold $PSX $WFC $CHTR $AAL $LUV $WMT $SNY Apple Is Now 26% Of The Portfolio https://www.investors.com/news/warren-buffett-stocks-berkshire-hathway-q3-13f/
  • woodman: $ESPR - we have (1) a tag off rising support (drawn from 11/14), (2) an inside and up after two inside days, and (3) a bullish engulfing candle. All after an extreme pre-market panic following pricing action on a competing drug of $REGN/$SNY.
  • rj7150: @steve71 $GKOS $SNY I have a note from this summer that Sanofi-Aventis was becoming a major competitor. I have no position in either.
  • Henry: @vfr777 $GKOS The local news had a report that scientists have discovered an ocular-protective molecule that could help glaucoma patients. It will be a while before that pans out. At about the same time, late yesterday, news hit that Bausch and Lomb (is that now part of $SNY ?) got FDA approval for a new drug to treat glaucoma.
  • vfr777: @Henry $GKOS $SNY Looks like it has stopped dropping and hit support of Sept at $30.22. All this news is not that great for holders of $GKOS. I'm holding and not too happy right now. Thanks for the information.
  • issues: Here's an article from IBD: French drugmaker Sanofi ($SNY) is reportedly considering a bid for Tesaro ($TSRO), but could face some competition from Gilead Sciences ($GILD), whose frustrated hepatitis C franchise has left the massive biotech thirsty f ...
  • tejas7: $SNY STO May 48 Calls/BTO May 49 calls for 0.87 Credit after trading fees. Stock goes ex-dividend tomorrow. It pays annual 1.577 per share at one time. (it is not special div. so not strike adjustment) Risking 0.13 for possible gain of 0.87 expecting price to fall below 48 in next 10 days
  • gwenzee: ...
    2) DUPIXENT (dupliumab) - atopic dermatitis - $SNY/$REGN
    3) SPINRAZA - Spinal muscular atrophy - $IONS/$BIIB - First FDA approval in Dec. '16 - 750 K for 1st yr. and 375K / yr. after that.
    4) SEMAGLUTIDE - Diabetes- $NVO - Victoza is strongest ...
  • BocaRick: $TSRO $SNY TSRO up 10 points on rumor of M+A with SNY. No news on Yhoo Finance or WSJ. #StockTwits full of Short This Stock comments on "Fake News"
  • crackleback: @BocaRick $TSRO $SNY #StockTwits This whatI found but no definite source mentioned, http://www.fool.com/investing/2017/01/26/heres-the-reason-behind-tesaro-incs-sudden-12-move.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2&yptr=yahoo
  • phgruver: @Kurt1 $JNJ Personally, I like big Pharma right here. Most of the big names have taken a hit, over the past month or so. $JNJ may be forming a short term bottom. I'm also looking at $BMY, $PFE, $LLY, $MRK and $SNY.
  • DrScience: @Spotdog $MYL Wonder where they're getting the generic epinephrine and pen from -- $SNY? $TEVA? -- because they obviously can't repackage their brand name product as a generic! I mean... it isn't, like, milk or bread, right? :)
  • Spotdog: @DrScience $MYL $SNY $TEVA They said they would launch with a "partner" but did not elaborate
  • woodman: @PJMR11 $MDVN Best of luck to you. I am torn over it. On the one hand, the last offer (from $SNY) it rejected was for $58 a share plus up to $3 more with a CVR. I'd think that is a floor. On the other hand, I don't like that CVS's PBM just announced it will not include Xtandi on its formulary. MDVN needs to report what that means to the company and its bottom line. MDVN also recently told the world that any potential suitor needs to make an offer, or state their intention to make an offer, by mid-August. Not sure where this leads to, but I figured I'd be cautious and cut back into earnings, then try to figure it all out afterward.
  • PJMR11: @woodman $MDVN $SNY Looks like the market agrees with you. Falling back before earnings
  • gwenzee: @agent99 $MDVN Has asked for indications of interest by Aug. 15. Among the possible suitors are $GILD, $PFE, $CELG and $SNY. Who will step up to the plate and at what price remains to be seen.
  • agent99: @gwenzee $MDVN $GILD $PFE $CELG $SNY Thanks. Someone is buying today. Volume is up.
  • gwenzee: @agent99 $MDVN $GILD $PFE $CELG $SNY Being able to see the light at the end of the tunnel seems positive. My cost basis is $18 so I'm elated.
  • agent99: @gwenzee $MDVN $GILD $PFE $CELG $SNY Thanks for alerting me to this.
  • woodman: @DAN $MDVN - I am unaware of a scuttled formal $65 bid from $SNY. I am aware of a bid from $SNY for $58 per share plus a CVR worth up to $3 that $MDVN has rejected. That is the highest published, or even rumored, bid that I am aware of, though I ha ...
  • champ: @captron $XON - The bill is for an anti-virus...no one has one yet as far as i know. Here are others that could be in play....$INO $CERS $SNY $TKPYT $GSK $APT and we all no about $LAKE. I picked $XON last week.
  • woodman: @shoredriver $MDVN -- $PFE just agreed to buy $ANAC for $5 billion, so I think $PFE is out of the running for $MDVN. $AMGN and $AZN the most likely candidates to compete against $SNY for $MDVN?
  • shoredriver: @woodman $MDVN $PFE $ANAC $AMGN $AZN $SNY my bet is $AMGN,but either way Sanofi needs to up their game if they really are interested and to get this moving.....thinking 16-18B looks possible..
  • Paddleboard: @Aragorn Early premarket gappers Gapping up: $VA +38.2%, $ZFGN 11.9%, $EW 7.9%, $SNY 4.1%, $TSLA 3.9%, $JCP 3.5%, $ESLT 3.2%, $NVO 2.3%, $ORAN 1.7%, $AZN 1.7%, $INO 1.6%, $HA 1.6%, $BP 1.3%, $RYAAY 1.3%, $ABB 1.2%, $TOT 1.2%, $RDS.A 1.1%, $TEVA 1.1%, $SSRI 1.1%, $RIO 0.9% Gapping down: $SUNE -34.9%, $SDRL -4.8%, $BCS -4.4%, $SWHC -2.7%, $GOLD -2.3%, $PBR -2%, $HNSN -1.9%, $ALK -1.5%, $TM -1.3%, $RBS -1.3%, $FB -1.2%, $DB -1.1%, $GDX -1%, $ABX -1%, $CS -0.9%, $SAN -0.9%, $VRX -0.5% Thanks for the post
  • traderbren: #Zika -- just an FYI for folks that are more knowledgeable on these stocks. I have a starter position in $XON a from lower level. Related Zika tickers: $SNY, $INO, $AEMD, $XON, $CEMI, $BCRX, $TMO, OTCQB: $GOVX
  • woodman: @traderbren $XON $SNY $INO $AEMD $CEMI $BCRX $TMO $GOVX #Zika #YellowFever - reading reports that Yellow Fever may be more problematic than Zika. At least in Africa, it could be terrible. Worse than Zika and SARS. And it's leaking outside of Africa to China and other places. $SNY makes the vaccine for Yellow Fever.
  • coldevinc: @woodman $XON $SNY $INO $AEMD $CEMI $BCRX $TMO $GOVX #Zika #YellowFever Zika, to me is very scary. Especially since the African nations are thinking of not coming over for the Olympics; because they don't want to bring it back to Africa
  • traderbren: @woodman $XON $SNY $INO $AEMD $CEMI $BCRX $TMO $GOVX #Zika #YellowFever - yikes, YellowFever! We're going from bad to worse. Looks like we've got some weekend research to do on this subject. Will take a closer look at $SNY Thanks
  • TRICIA: #ZIKA $XON, $INO, $SNY eytx... Puerto Rico to be ground zero of U.S. Zika epidemic On an inexorable march across the hemisphere, the Zika virus has begun spreading through Puerto Rico, now the United States' front line in a looming epidemic.A quarter of the island's 3.5M people will likely get the Zika virus within a year, according to the Centers for Disease Control and Prevention, and eventually 80% or more may be infected.The territory's first Zika case was confirmed in December, and the governor declared a health emergency on Feb. 5.
  • freno: $XON - $SNY another Pharma looking for Zika virus vaccine.
  • Lou: Interesting spec by a $TWTR poster - if $MRK bids for $RLYP, $SNY and $AMGN may want to get in on the bidding. Sounds right to me as $SNY has very large stake in $RLYP and a deal on the distribution.
  • woodman: @Lou $TWTR $MRK $RLYP $SNY $AMGN A friend of mine at SNY is not aware of any interest that SNY has in RLYP. They are tied to another company.
  • Lou: @woodman $RLYP $SNY call your friend's attention to this article: http://investor.relypsa.com/releasedetail.cfm?releaseid=926942
  • woodman: @Lou $RLYP $SNY Just getting back from some errands, and seeing this. I will send this to him. Thanks, Lou.
  • woodman: @Lou $RLYP Hey, Lou, thanks for that $SNY info. I will pass it on to my friend. Just goes to show that he may not be one who's in the know on stuff like this (though he isn't a low-totem pole guy) :-?
  • Prazan: @luongobill12 @Aragorn Here's the list of BUG & FlU tickers @Tricia initiated in the forum several weeks ago, with a few changes: $IBIO,$TKMR,$CEMP,$AKAO,$ACT,$CBST,$NBY,$MDCO,$BCRX,$TTPH,$NVAX,$SNY,$DRTX,$HEB,$ENTA,$DVAX Note that his list includes companies in the antibiotics field, $CEMP notable among them.
  • rj7150: @teeka99 $MNKD As a short term trade who knows. Long term if it works for your particular insulin requirements, it is a no brainer. I worked with a fellow who had to give himself a needle just before he ate every meal. If this works, I'm sure he would rather use this product. One positive hint from the conference call is that $SNY is wanting away more sample kits than they had anticipated requiring for the launch. That tells me their is lots of interest. Anyone wanting to switch to this has to see a doctor and get a prescription to use it. This will slow the sales a little time wise. It will take the next quarterly report or two to tell the tale. I held over earnings and will continue. It is not a large holding. Good luck to all what ever your strategy.
  • gwenzee: @lostsheep $MNKD - Named after Al Mann who is very hands on and commited to his company and making lives better for those who have chronic illnesses. This is his "baby" and IMO he is not interested in selling it at this time. Also IMO Affrezza will have to prove itself before any company ($SNY) would probably buy it.
  • RON: The Components’ of Berkshire Hathaway $BRKB Closing the LOD Lists are sorted in Relation to the 50 MA $USG the highest above the 50 and $CBI the farthest below the 50 Above the 50MA -- $USG $GHC a rev down $KRFT $VRSK $COST $DNOW $PSX $DVA $SNY 9 of 47 Below the 50MA -- $V $DTV $WMT $GM $LMCK $LMCA $WFC $LBTYK $ESRX $IBM $LBTYA $SU $KO $VZ $USB $JNJ $MA $MCO $VRSN $XOM $GE $TMK $COP $MDLZ $PG $WBC $MTB $CHTR $GS $BK $UPS $MEG $AXP $VIAB $PCP $NOV $LEE $CBI Above the 8EMA -- $USG $GHC $VRSK $COST $DNOW $PSX -- $V $SU and Below the 50MA $UNP at the 50MA, 118.08 with Lower Highers and Lower Lows in consolidation using $UNP as a proxy for Santa Fe Burlington Northern owned out right by Berkshire, last accumulated at 110.00 on heavy volume, now rolling lower
  • hawk327: @mradams0621 $FEYE Looking for rotation, in the market. This seems like it has possibilities. With hack into $SNY bringing cyber security into the head lines and this stock having 6 months of low volatility building a base. A stop just below solid support seems like a low risk entry to me. No position
  • traderbren: Some pre-mkt movements: $ARCP, -15% $FB, -6.5% $INVN, -21% $SNY, -5% $BABA, 0.3% $CARA, 15.5% $HIVE, -11.4% $CHRW, 3.6% $GILD, -2.7% $CLF, 0.6% $ORB, -14% $SODA, -4.1% $HSY, -3.7% $STM, -10.5% $AMCC, -10.6% $X, 8.5% $GT, 5.2% $EA, 2.7% $SKYW, 1.4% $BLDP, -5.3% $PNRA, -3% $WDC, -1.7%
  • boba: $UNIS - Huge breakout on news of long term deal w/ $SNY, Sanofi.
  • Tricia: $ITMN: popping on rumor $RHHBY, $SNY takeover .. (would be a good fit BUT Roche has sux's at takeover attempts ....if you are not in this ... WAIT ...
  • Tricia: $MNKD - up 25% PM ...inked a $925 M partnership with $SNY - http://www.fiercebiotech.com/story/sanofi-fills-some-big-shoes-925m-afrezza-pact-mannkind/2014-08-11?utm_medium=rss&utm_source=rss&utm_campaign=rss
  • Forexpro: ...
    $BRKS, $AHT, $PG, $EXC, $ISIL, $BSMX,$TRNO, $K, $LLL, $EIX, $AXS,$RGP, $FNF,$MCHP, $MCC,$MWP, $SBRA,$TSU, $BWP, $RGC, $KRFT, $DUK, $CLX, $NYRT, $GIS, $XLS, $CL, $SIMO, $NRF, $HCN, $GGN, $HCT, $SNY, $NLY

    Most of these names are, of course, defensive ...
  • Tricia: @levnor18 $MACK follow it but not invested...here is an article - suggest you read the comments also .. Sanofi gave back the rights to their star panc ca candidate 6-7 weeks ago ..http://seekingalpha.com/article/2303985-is-now-the-time-to-buy-merrimack-pharmaceuticals Edited points ... -MACK has multiple shots on goal, but odds are still against it. -$SNY return of MM-121 cannot be taken lightly--- - prospects can be rooted in the success of one drug, which has its own relevant implications. - it shouldn't hurt to simply wait on the sidelines until more unravels.
  • DrScience: $REGN #TradeIdea While you were wondering how to get involved in a $310 stock with a month to go before earnings are released, Sanofi ($SNY) was in the market, buying another 750K shares of Regeneron since July 1.

    http://www.finviz.com/insidertradin ...
  • rj7150: @jwstich $REGN I just finished watching the annual meeting webcast. There was nothing in it that would suggest trouble on the horizon. $SNY owns over 20 million shares which is about 20% if I have done the math correctly. Sanofi is putting a billion dollars a year into research through REGN. The CFO is retiring after 18 to 20 years with the company. He has white hair and probably enough money. If someone knows of a threat to REGNs future please let us know.
  • bullmoose: $EMC, $SNY - Dipped my toes into both of these today. I'm a bit late on both but like the weekly charts, especially on EMC. I'll keep tight stops on both.
  • Tricia: REGN: and $SNY : $REGN iis halted or it was .. ...http://www.financialjuice.com/News/759899/Regeneron-Pharmaceuticals-REGN-and-Sanofi-SNY-advised-by-the-FDA-that-it-has-become-aware-of-neurocognitive-adverse-events-in-the-PCSK9-inhibitor-class.aspx I don't belong to financial juice .. DAMMIT ... why doesn't #CNBC or Bloom have this ... they need some real healthcare gerus - not all these stupid blowheards! I don't give damn about $HLF .. I care about people and the economy a... and anyone who doesn't think our economic growth is hostage to the overall state if health care is just plain ...
  • par: REGN-halted-Regeneron Pharmaceuticals $REGN and Sanofi $SNY advised by the FDA that it has become aware of neurocognitive adverse events in the PCSK9 inhibitor class
Visit the Trading Forum to join in the discussion.
Stock Price $47.44
Change -0.79%
Volume 2,309,470

Sanofi is a healthcare company focused on patient needs and engaged in the research, development, manufacture and marketing of healthcare products. The Company also discovers, develops and distributes therapeutic solutions.

Request Video of SNY
Already a member? Sign in here.
Past Month

Leading Peers

Past Month

Lagging Peers

Dan Fitzpatrick

Stock Market Mentor gives you EVERYTHING you need to succeed in the market; all in one place. How easy is that? Dan Fitzpatrick and his elite community of traders share trading ideas, strategies and much more. Dan Fitzpatrick--a world class Technical Analyst, trading coach and regular CNBC contributor--gives you access to all of this with a 30 day trial membership for just $7.77. Get started TODAY and start trading better TOMORROW with the following premium content:

  • Nightly video Strategy Sessions with a game plan for tomorrow
  • Got a stock you want Dan to look at? Just ask.
  • Patent pending video alerts instantly delivered to you when one of Dan’s trading signals is triggered. This is not your typical price alert. This is a short video explaining the action you need to take to make money. No more “Woulda, coulda, shoulda”
  • Access to over 90,400 stock analysis videos
  • Access an ever expanding library (90,400) of educational videos that will save you time and make you money

Join a team of friends and traders that have one thing in common; a burning desire to succeed.

Become a Member Today!

Gain immediate access to all our exclusive articles, features, how-to's, discussion group and much more...

Satisfaction Guaranteed!

Your Stock Market Mentor membership comes with a 30 day, no questions asked, 100% money back guarantee!